LLY
Eli Lilly and Company
LLY has the edge over NVCR overall, supported by lower modeled downside and stronger fundamentals.
NVCR
NovoCure Limited
NVCR's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVCR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
NVCR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NVCR PE Valuation
NVCR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NVCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NVCR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NVCR on earnings quality, reporting a profit while its opponent remains loss making.
NVCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | +$0.55 |
| Q2 2026 | -$1.30 | +$0.26 |
| Q1 2026 | -$1.53 | -$0.02 |
| Q4 2025 | -$1.22 | +$0.34 |
| Q3 2025 | -$1.61 | -$0.21 |
| Q2 2025 | -$1.56 | +$0.02 |
| Q1 2025 | -$1.51 | +$0.30 |
| Q4 2024 | -$1.56 | +$0.39 |
NVCR is still losing money, but less than at its worst: $1.06 per share over the past year, against $1.95 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NVCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NVCR on profitability, with a higher operating margin.
NVCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $193.4M | +16% |
| Q2 2026 | $183.6M | +16% |
| Q1 2026 | $174.1M | +12% |
| Q4 2025 | $174.4M | +8.1% |
| Q3 2025 | $167.2M | +7.8% |
| Q2 2025 | $158.8M | +5.6% |
| Q1 2025 | $155M | +12% |
| Q4 2024 | $161.3M | +21% |
NVCR's revenue has grown year over year for 12 quarters in a row: $193M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.2% | +18 points |
| Q2 2026 | -5.8% | +19 points |
| Q1 2026 | -39% | -14 points |
| Q4 2025 | -23% | +16 points |
| Q3 2025 | -22% | -0.8 points |
| Q2 2025 | -25% | -2.6 points |
| Q1 2025 | -24% | +5.6 points |
| Q4 2024 | -39% | -0.6 points |
NVCR's operating margin was −3.2% last quarter, up 18 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NVCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
NVCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.7M | +5.5% |
| Q2 2026 | $1.2M | +$22.6M |
| Q1 2026 | -$18.7M | +$27.6M |
| Q4 2025 | -$22.9M | -$10.5M |
| Q3 2025 | $14.9M | +$15.2M |
| Q2 2025 | -$21.4M | -$8.3M |
| Q1 2025 | -$46.3M | -$2.9M |
| Q4 2024 | -$12.4M | +$9M |
NVCR's free cash flow was −$25M over the past year, against −$65M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NVCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NVCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +773K shares |
| 1 year | +4.4% | +4.9M shares |
| 3 years | +9.4% | +10M shares |
| 5 years | +13% | +13.1M shares |
| Available history | +8.2% | +8.9M shares |
NVCR has 117M diluted shares, up 4.4% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NVCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -105.8x | Net Cash |
| Q2 2021 | 8.7x | High |
| Q1 2021 | 5.7x | High |
| Q4 2020 | 4.9x | High |
| Q3 2020 | -8.5x | Net Cash |
| Q2 2020 | -2.9x | Net Cash |
| Q1 2020 | -3.2x | Net Cash |
| Q4 2019 | -3.7x | Net Cash |
NVCR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NVCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 14.2 | Oversold |
NVCR's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NVCR PE vs Healthcare Sector
| Metric | NVCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NVCR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NVCR on trend strength, trading above more of its moving averages.
NVCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 16% below |
| 20 week MA | $15.6 | 25% below |
| 50 week MA | $14.5 | 19% below |
| 100 week MA | $16.0 | 27% below |
| 200 week MA | $23.3 | 50% below |
NVCR is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NVCR on returns for 2026, with the stronger performance.
NVCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.6 | $172.0 | +96% |
| 2021 | $172.0 | $84.0 | -51% |
| 2022 | $84.0 | $73.0 | -13% |
| 2023 | $73.0 | $14.9 | -80% |
| 2024 | $14.9 | $30.7 | +106% |
| 2025 | $30.7 | $13.5 | -56% |
| 2026 YTD | $13.5 | $11.7 | -13% |
NVCR's yearly returns have swung widely, from +106% in 2024 to −80% in 2023. It's down 13% so far in 2026.